# Ajanta Pharma (NSE: AJANTPHARM) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/AJANTPHARM · Pivot · prices to 22 Oct 2026

Ajanta Pharma (NSE: AJANTPHARM) closed at ₹3,260.00 on 22 Oct 2026, up 0.00% on the day. With a market capitalisation of ₹40,861 Cr, it ranks 221st by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 38.6× trailing earnings, against a return on equity of 23.3% in FY26. Over the past year the share price has risen 36.1%. Its 52-week range is ₹2,382.00 (28 Oct 2025) to ₹3,796.00 (18 Aug 2026); the last close is 14.1% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹1,626 Cr (+24.8% year on year) and net profit ₹334 Cr (+30.9%), on a consolidated basis. Promoters held 63.48% of the company as of 30 Jun 2026; 22.53% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹3,260.00 |
| Market cap | ₹40,861 Cr |
| P/E (trailing) | 38.6 |
| ROE | 23.3% (FY26) |
| ROCE | 29.4% (FY26) |
| Debt to equity | 0.05 |
| 52-week high | ₹3,796.00 (18 Aug 2026) |
| 52-week low | ₹2,382.00 (28 Oct 2025) |
| 1-year return | +36.1% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹1,626 Cr | +24.8% | ₹334 Cr | +30.9% | ₹26.75 |
| Q4 FY26 | ₹1,422 Cr | +21.5% | ₹267 Cr | +18.4% | ₹21.35 |
| Q3 FY26 | ₹1,375 Cr | +20.0% | ₹274 Cr | +17.6% | ₹21.91 |
| Q2 FY26 | ₹1,354 Cr | +14.1% | ₹260 Cr | +20.2% | ₹20.83 |
| Q1 FY26 | ₹1,303 Cr | +13.8% | ₹255 Cr | +3.9% | ₹20.44 |
| Q4 FY25 | ₹1,170 Cr | +11.0% | ₹225 Cr | +11.1% | ₹18.00 |
| Q3 FY25 | ₹1,146 Cr | +3.7% | ₹233 Cr | +10.9% | ₹18.60 |
| Q2 FY25 | ₹1,187 Cr | +15.4% | ₹216 Cr | +10.8% | ₹17.27 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹4,648 Cr | ₹920 Cr |
| FY24 | ₹4,209 Cr | ₹816 Cr |
| FY23 | ₹3,743 Cr | ₹588 Cr |
| FY22 | ₹3,341 Cr | ₹713 Cr |
| FY21 | ₹2,890 Cr | ₹654 Cr |
| FY20 | ₹2,588 Cr | ₹468 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 63.48%
- Foreign institutions: 7.68%
- Domestic institutions: 21.80%
- Non-institutions: 7.03%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [IPCA Laboratories](https://app.pivotnow.in/stock/IPCALAB) | ₹1,932.90 | ₹48,293 Cr | 43 | 14.2% |
| [Gland Pharma](https://app.pivotnow.in/stock/GLAND) | ₹2,910.60 | ₹47,020 Cr | 46.7 | 9.9% |
| [Anthem Biosciences](https://app.pivotnow.in/stock/ANTHEM) | ₹802.40 | ₹45,113 Cr | 76.6 | 19.4% |
| [GlaxoSmithKline Pharmaceuticals](https://app.pivotnow.in/stock/GLAXO) | ₹2,455.20 | ₹41,228 Cr | 40.1 | 47.7% |
| [Narayana Hrudayalaya](https://app.pivotnow.in/stock/NH) | ₹1,691.90 | ₹34,602 Cr | 42.4 | 17.8% |
| [Emcure Pharmaceuticals](https://app.pivotnow.in/stock/EMCURE) | ₹1,759.20 | ₹33,812 Cr | 145.1 | 18.7% |

## Questions and answers

### What is the share price of Ajanta Pharma today?

Ajanta Pharma (NSE: AJANTPHARM) last closed at ₹3,260.00 on 22 Oct 2026. Its 52-week high is ₹3,796.00 and its 52-week low is ₹2,382.00.

### What is the market cap of Ajanta Pharma?

Ajanta Pharma's market capitalisation is ₹40,861 Cr (₹40,861 Cr) at the 22 Oct 2026 close, ranking 221st among the NSE companies Pivot tracks.

### What is the P/E ratio of Ajanta Pharma?

Ajanta Pharma trades at a trailing P/E of 38.6. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 46.7.

### What is the ROE and ROCE of Ajanta Pharma?

Return on equity was 23.3% in FY26 and return on capital employed was 29.4% in FY26 (consolidated figures).

### Is Ajanta Pharma a debt-free company?

Ajanta Pharma is close to debt-free: its debt-to-equity ratio was 0.05 in FY26.

### What were Ajanta Pharma's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Ajanta Pharma reported revenue of ₹1,626 Cr, +24.8% year on year, and net profit of ₹334 Cr, +30.9% year on year.

### How has Ajanta Pharma stock performed over the last year?

Ajanta Pharma's share price has risen 36.1% over the past year, −5.8% over three months and −7.4% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Ajanta Pharma?

As of 30 Jun 2026: promoters 63.48%, foreign institutions 7.68%, domestic institutions 21.80%, non-institutions 7.03%. 22.53% of promoter shares were pledged.

### Who are Ajanta Pharma's competitors?

The listed Pharma & Healthcare companies closest to Ajanta Pharma by market cap are IPCA Laboratories, Gland Pharma, Anthem Biosciences, GlaxoSmithKline Pharmaceuticals, Narayana Hrudayalaya and Emcure Pharmaceuticals.

### Is Ajanta Pharma a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Ajanta Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on AJANTPHARM against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.